Wellington Management Group
CNCE

Wellington Management Group’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Wellington Management Group’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-27,380
Closed -$407K – 2244
2018
Q3 		$407K Hold
27,380
– – ﹤0.01% 2087
2018
Q2 		$461K Hold
27,380
– – ﹤0.01% 2059
2018
Q1 		$627K Buy
27,380
+5,840
+27% +$130K ﹤0.01% 1985
2017
Q4 		$558K Buy
+21,540
New +$434K ﹤0.01% 2021

Other funds holding CNCE

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wellington Management Group's CNCE Position: Q4 2018 in Review

Wellington Management Group sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q4 2018, closing a stake of 27,380 shares — an estimated $407K sold.

Wellington Management Group first reported a position in CNCE in Q4 2017 and held it in 4 quarters. The position peaked at $627K in Q1 2018. 93 funds tracked by Wall St. Rank hold CNCE as of Q4 2018.

  • Wellington Management Group reported no remaining Concert Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
  • Wellington Management Group sold 27,380 Concert Pharmaceuticals, Inc. shares in Q4 2018, an estimated $407K.
  • Wellington Management Group first reported a position in Concert Pharmaceuticals, Inc. in Q4 2017 and held it in 4 quarters.
  • Wellington Management Group's Concert Pharmaceuticals, Inc. position peaked at $627K in Q1 2018.
  • 93 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q4 2018.

Based on Wellington Management Group's 13F filing for Q4 2018, filed 14 Feb 2019.